{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-037819","form_type":"8-K","ticker":"RAPH","cik":"0001415397","company_name":"Raphael Pharmaceutical Inc.","filed_at":"2022-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.674529+00:00","generated_at":"2026-06-24T19:20:38.074397+00:00","sec_items":["4.01","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Raphael Pharma dismisses Deloitte auditor, Chairman Press resigns; new exec comp agreements","bullets":["Dismissed Brightman Almagor Zohar (Deloitte) as auditor; appointed Weinstein International as new independent auditor.","Chairman Prof. Joseph Press resigned from board effective June 30, 2022; consulting fee $1,000/meeting, 280k shares, 105k warrants at $1.12.","CEO Shlomo Pilo (Sheffa Enterprises) gets new management agreement: $10k/mo (2022) then $20k/mo, 1M warrants at $1.12, expires Dec 2024.","CFO Guy Ofir gets operations agreement: $6k/mo (2022) then $12k/mo, 1M restricted shares, 1M warrants at $1.00, expires Dec 2024.","CTO Dr. Igal Louria Hayon: $9k/mo (2022) then $12k/mo, 990k warrants at $0.01, plus 15% of royalties from cannabis COVID and RA indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-037819","json":"https://secwatch.observer/filing/0001213900-22-037819.json","markdown":"https://secwatch.observer/filing/0001213900-22-037819.md","text":"https://secwatch.observer/filing/0001213900-22-037819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1415397/000121390022037819/0001213900-22-037819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1415397/000121390022037819/ea162555-8k_raphael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T19:20:38.074397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32befa6733","claim":"Joseph Press resigned as Chairman of the Board of Directors at Raphael Pharmaceutical Inc..","evidence_excerpt":"On June 30, 2022, Prof. Joseph Press informed the Company that he intended to resign from the Board of Directors, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1415397/000121390022037819/0001213900-22-037819-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}